163 related articles for article (PubMed ID: 9437511)
1. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation.
Greenwald RA; Golub LM; Ramamurthy NS; Chowdhury M; Moak SA; Sorsa T
Bone; 1998 Jan; 22(1):33-8. PubMed ID: 9437511
[TBL] [Abstract][Full Text] [Related]
2. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.
Ryan ME; Usman A; Ramamurthy NS; Golub LM; Greenwald RA
Curr Med Chem; 2001 Feb; 8(3):305-16. PubMed ID: 11172685
[TBL] [Abstract][Full Text] [Related]
3. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases.
Sorsa T; Ramamurthy NS; Vernillo AT; Zhang X; Konttinen YT; Rifkin BR; Golub LM
J Rheumatol; 1998 May; 25(5):975-82. PubMed ID: 9598901
[TBL] [Abstract][Full Text] [Related]
4. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.
Holmes SG; Still K; Buttle DJ; Bishop NJ; Grabowski PS
Bone; 2004 Aug; 35(2):471-8. PubMed ID: 15268899
[TBL] [Abstract][Full Text] [Related]
5. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.
Vernillo AT; Ramamurthy NS; Golub LM; Rifkin BR
Curr Opin Periodontol; 1994; ():111-8. PubMed ID: 8032451
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase.
Billinghurst RC; Wu W; Ionescu M; Reiner A; Dahlberg L; Chen J; van Wart H; Poole AR
Arthritis Rheum; 2000 Mar; 43(3):664-72. PubMed ID: 10728761
[TBL] [Abstract][Full Text] [Related]
7. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).
Dahlberg L; Billinghurst RC; Manner P; Nelson F; Webb G; Ionescu M; Reiner A; Tanzer M; Zukor D; Chen J; van Wart HE; Poole AR
Arthritis Rheum; 2000 Mar; 43(3):673-82. PubMed ID: 10728762
[TBL] [Abstract][Full Text] [Related]
8. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs.
Rifkin BR; Vernillo AT; Golub LM
J Periodontol; 1993 Aug; 64(8 Suppl):819-27. PubMed ID: 8410621
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
[TBL] [Abstract][Full Text] [Related]
10. Chondrocyte matrix metalloproteinase-8: up-regulation of neutrophil collagenase by interleukin-1 beta in human cartilage from knee and ankle joints.
Chubinskaya S; Huch K; Mikecz K; Cs-Szabo G; Hasty KA; Kuettner KE; Cole AA
Lab Invest; 1996 Jan; 74(1):232-40. PubMed ID: 8569187
[TBL] [Abstract][Full Text] [Related]
11. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.
Little CB; Flannery CR; Hughes CE; Mort JS; Roughley PJ; Dent C; Caterson B
Biochem J; 1999 Nov; 344 Pt 1(Pt 1):61-8. PubMed ID: 10548534
[TBL] [Abstract][Full Text] [Related]
12. Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.
Gu Y; Lee HM; Simon SR; Golub LM
Pharmacol Res; 2011 Dec; 64(6):595-601. PubMed ID: 21651982
[TBL] [Abstract][Full Text] [Related]
13. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro.
Bau B; Gebhard PM; Haag J; Knorr T; Bartnik E; Aigner T
Arthritis Rheum; 2002 Oct; 46(10):2648-57. PubMed ID: 12384923
[TBL] [Abstract][Full Text] [Related]
14. Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs.
Rifkin BR; Vernillo AT; Golub LM
J Periodontol; 1993 Aug; 64 Suppl 8S():819-827. PubMed ID: 29539753
[TBL] [Abstract][Full Text] [Related]
15. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer.
Lee HM; Golub LM; Cao J; Teronen O; Laitinen M; Salo T; Zucker S; Sorsa T
Curr Med Chem; 2001 Feb; 8(3):257-60. PubMed ID: 11172680
[TBL] [Abstract][Full Text] [Related]
16. Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants.
Piecha D; Weik J; Kheil H; Becher G; Timmermann A; Jaworski A; Burger M; Hofmann MW
Inflamm Res; 2010 May; 59(5):379-89. PubMed ID: 19902332
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase.
Hill PA; Docherty AJ; Bottomley KM; O'Connell JP; Morphy JR; Reynolds JJ; Meikle MC
Biochem J; 1995 May; 308 ( Pt 1)(Pt 1):167-75. PubMed ID: 7755562
[TBL] [Abstract][Full Text] [Related]
18. CMT-3 inhibits orthodontic tooth displacement in the rat.
Bildt MM; Henneman S; Maltha JC; Kuijpers-Jagtman AM; Von den Hoff JW
Arch Oral Biol; 2007 Jun; 52(6):571-8. PubMed ID: 17174265
[TBL] [Abstract][Full Text] [Related]
19. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures.
Kozaci LD; Buttle DJ; Hollander AP
Arthritis Rheum; 1997 Jan; 40(1):164-74. PubMed ID: 9008612
[TBL] [Abstract][Full Text] [Related]
20. Relaxin's induction of metalloproteinases is associated with the loss of collagen and glycosaminoglycans in synovial joint fibrocartilaginous explants.
Naqvi T; Duong TT; Hashem G; Shiga M; Zhang Q; Kapila S
Arthritis Res Ther; 2005; 7(1):R1-11. PubMed ID: 15642129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
